Mutations in the genes encoding for Met, Ret and Kit receptor tyrosine kinases invariably result in increased kinase activity and in the acquisition of transforming potential. However, the requirement of receptor ligands for the transformation process is still unclear. We have investigated the role of hepatocyte growth factor (HGF), the high-anity ligand for Met, in mutant Met-mediated cell transformation. We provide evidence that the transforming potential displayed by mutant forms of Met found in human cancer is not only sensitive but entirely dependent on the presence of HGF, by showing that mutant Met transforms NIH3T3 ®broblasts, which produce endogenous HGF, but is not able to transform epithelial cells, unless exogenous HGF is supplied. Accordingly, mutant Met-induced transformation of NIH3T3 cells can be inhibited by HGF antagonists and increased by HGF stimulation. We also show that an engineered Met receptor which contains an oncogenic mutation but is impaired in its ability to bind HGF completely loses its transforming activity, which can be rescued by causing receptor dimerization using a monoclonal antibody. These results indicate that point mutations resulting in Met kinase activation are necessary but not sucient to cause cell transformation, the latter being dependent on ligand-induced receptor dimerization. They also suggest that mutant Met-driven tumour growth depends on the availability and tissue distribution of active HGF, and provide proof-of-concept for the treatment of mutant-Met related pathologies by HGF-antagonizing drugs.
Introduction
The Met tyrosine kinase is a high-anity receptor for hepatocyte growth factor (HGF), a cytokine that is ubiquitously expressed by cells of mesenchimal origin (Bottaro et al., 1991; Naldini et al., 1991) . The Met receptor is expressed mainly by epithelial cells (Stoker et al., 1987; Di Renzo et al., 1991) , but it has also been identi®ed in endothelial cells (Bussolino et al., 1992; Grant et al., 1993) , in myoblasts (Anastasi et al., 1997) , in cells of the hematopoietic system (Galimi et al., 1994; Nishino et al., 1995) and in spinal motor neurons (Ebens et al., 1996) . Signalling through HGF/ Met promotes a unique biological program known as invasive growth' that results from the integration of distinct cellular responses, that include cell division, cell motility, extracellular matrix digestion and invasion, survival and morphogenetic dierentiation Tamagnone and Comoglio, 1997; Rubin et al., 1993) . HGF/Met signalling is essential for mouse embryo development Schmidt et al., 1995; Uehara et al., 1995; Maina et al., 1996) and is believed to play a key role in tissue regeneration (Matsumoto and Nakamura 1993) , wound healing (Nusrat et al., 1994) , and organ development Schmidt et al., 1995; Woolf et al., 1995; Yang et al., 1995) . Inappropriate activation of the HGF/Met pathway has been implicated in the etiology of a number of tumours and has been shown to promote the metastatic spread of neoplastic cells (Di Renzo et al., 1991 , 1995 Giordano et al., 1997; Jeers et al., 1996; Vande Woude et al., 1997) .
Recently, a more direct link between Met and cancer has been provided by the identi®cation of point mutations in the Met proto-oncogene in hereditary and sporadic papillary renal carcinomas (PRC; Schmidt et al., 1997 Schmidt et al., , 1998 . Duplication of the mutant Met allele has also been detected in hereditary PRC (Zhuang et al., 1998; Fischer et al., 1998) . These mutations (hereafter referred to as Met PRC mutations) result in amino acid substitutions in the kinase domain of Met, and some of them are homologous to previously identi®ed mutations in the genes encoding for Ret and Kit. In the Ret gene germ-line mutations resulting in amino acid substitutions in the extracellular portion and in the kinase domain of Ret are associated with multiple endocrine neoplasia syndrome type 2A (MEN2A) and type 2B (MEN2B), respectively (Mulligan et al., 1993; Hofstra et al., 1994) . Somatic mutations in the Kit gene that cause amino acid substitutions in the kinase domain or juxtamembrane domain of Kit have been found in mastocytomas (Nagata et al., 1995; Longley et al., 1996) and in tumours of the gastro-intestinal tract , respectively. Familial gastro-intestinal stromal tumours have also been linked to a germ-line mutation in the Kit gene that corresponds to a single amino acid substitution in the juxtamembrane domain of Kit .
These amino acid substitutions invariably result in increased kinase activity and in acquisition of transforming potential, both in vitro and in vivo (Santoro et al., 1995; Borrello et al., 1995; Moriyama et al., 1996; Kitayama et al., 1996; Jeers et al., 1997; Bardelli et al., 1998) , thus implicating aberrant kinase activation in tumour etiology. However, the role played by receptor ligands in the mediation of the transformed phenotype is still unclear. Transformation mediated by the MEN2B Ret mutant can be increased by in vitro stimulation with the Ret ligand GDNF (glial cell line-derived neurotrophic factor; Bongarzone et al., 1998) . In contrast, MEN2A Ret mutants are insensitive to GDNF stimulation (Carlomagno et al., 1998) . Both juxtamembrane and kinase domain Kit mutants display constitutive tyrosine phosphorylation which is insensitive to stimulation with the Kit ligand SFC (stem cell factor; Nishida et al., 1998) , and support factor-independent growth of ematopoietic cells in vitro (Kitayama et al., 1995) .
In the case of Met, the issue is complicated by the fact that NIH3T3 ®broblasts, that have been used as the sole host cell line for transformation assays (Jeers et al., 1997; Bardelli et al., 1998) , produce signi®cant amounts of HGF (see Results). So far, the function of endogenous HGF in NIH3T3 transformation by Met PRC mutants has not been investigated. Interestingly, papillary renal carcinomas are associated with chromosome 7 trisomy, on which both the Met and HGF genes lie (Zhuang et al., 1998; Fischer et al., 1998) . Furthermore, patients carrying germ-line mutations in the Met gene develop kidney tumours only late in life (Schmidt et al., , 1998 , suggesting that other agents, genetic or environmental, contribute to the development of this neoplastic disorder. This landscape-dependent' phenotype (Kinzler and Vogelstein, 1998 ) of hereditary PRC prompted us to investigate whether the Met ligand HGF could be one of these factors that in¯uence the occurrence of PRC, to which mutations in the Met proto-oncogene predispose.
In this study, we have analysed the role of HGF in mutant Met-mediated cell transformation using NIH3T3 ®broblasts and MDCK kidney epithelial cells. We provide evidence that transformation mediated by Met PRC mutants is not only responsive to HGF stimulation but also dependent on the presence of HGF and on its interaction with the receptor.
Results

HGF increases mutant Met-induced transformation of NIH3T3 ®broblasts
Nine mutations in the kinase domain of Met identi®ed in human PRC were introduced into a human Met cDNA and the wild-type or mutant cDNAs subcloned into the expression vector pCEV29.1, which carries the G418 resistance, as described (Bardelli et al., 1998) . A cDNA encoding for human HGF was subcloned into the expression vector pBABE, which carries the resistance to puromycin (Morgenstern and Land, 1990) . To determine the responsiveness of mutant Met to ligand stimulation, NIH3T3 cells were cotransfected with the pCEV29.1 vector containing wildtype or mutant Met together with the pBABE vector containing either no insert or human HGF. As a control, cells were also transfected with the empty pCEV29.1 vector together with pBABE containing either no insert or human HGF. Following transfection, cells were split into four plates; three plates were utilized for a focus forming assay and the fourth to obtain stable transfectants resistant to both G418 and puromycin. All plates contained a comparable number of resistant colonies, indicating that eciency was similar for all transfections.
As shown in Figure 1a , HGF increased the focus forming ability of all nine mutants analysed, but did not increase the number of foci induced by wild-type Met, which was identical to the background. The background is represented by the number of foci yielded by transfections of the empty vectors. Next, the anchorage-dependency of stable transfectants expres-sing ectopic Met/HGF was tested in a soft agar assay. All cell lines expressing both a Met PRC mutant and HGF formed more colonies in soft agar compared with cells expressing the same Met PRC mutant alone ( Figure  1b ). Western blot analysis of ectopic proteins revealed that all cell lines expressed comparable levels of Met and secreted similar amounts of HGF ( Figure 1c) . Thus, it can be concluded that transformation mediated by mutant Met is sensitive to HGF stimulation.
HGF is required for mutant Met-induced transformation of epithelial cells
NIH3T3 ®broblasts are the most used cell system to assay oncogene-mediated transformation. However, b c Figure 1 HGF increases mutant-Met mediated transformation of NIH3T3 cells. (a) Focus forming activity of mutant Met in the absence or presence of exogenous HGF. Cells were co-transfected with the pCEV29.1 vector containing wild-type or mutant human Met together with the pBABE vector containing either no insert or a human HGF cDNA. As a control, cells were also cotransfected with the empty pCEV29.1 vector together with pBABE containing either no insert or human HGF. Foci were scored two weeks after transfection. Values are the mean of four experiments conducted in triplicate and the bars indicate standard deviation. The ®gure inset shows representative plates from one experiment. (b) Mutant Met-induced anchorage-independent growth of NIH3T3 in the absence or presence of exogenous HGF. Stable cell lines from the transfections described in a were tested for their ability to form colonies in soft agar. Colonies were scored two weeks after seeding. Values are the mean of two experiments conducted in triplicate and the bars indicate standard deviation. The ®gure inset shows representative ®elds from one experiment. (c) Western blot analysis of stable cell lines obtained from the transfections described in a. Cell lysates were resolved by SDS ± PAGE and analysed by Western blotting using anti-Met antibodies (top panel) or anti-HGF antibodies (middle panel). Conditioned medium was precipitated using heparin-coated sepharose-protein A beads, resolved by SDS ± PAGE and analysed by Western blotting using anti-HGF antibodies (bottom panel). The Met protein is present in the unprocessed (p175) and mature (p145) forms. Analysis of HGF expression using anti-b-chain antibodies detects pro-HGF in cell lysates and the two dierentially glicosylated forms of HGF b-chain (b 1 and b 2 ) in the medium. The two forms of exogenous human HGF migrate dierently due to the presence of a poly-His tag (bottom panel; see Materials and methods) when testing the transforming activity of an oncogene encoding for a receptor, the possible presence of its ligand should be taken into account. We observed that HGF levels secreted by NIH3T3 were prone to increase with cell passage number and following selection with G418 and puromycin. Untransfected cells at early passages secreted 2 ± 4 scatter units of HGF, while cells that had undergone transfection and selection could produce up to 30 scatter units of HGF. Cross-reaction between mouse HGF and human Met occurs, and can therefore mediate biological responses (Bussolino et al., 1992) . Thus, it is conceivable that transformation mediated by mutant, human Met in NIH3T3 cells can depend at least in part on the presence of endogenous HGF.
As mentioned above, Met is normally expressed in cells of epithelial origin, and germ-line mutations in the kinase domain of Met result in the development of papillary renal carcinomas. To study Met-induced transformation in a system that is closer to physiologic conditions and that is free of HGF, we expressed mutant or wild-type Met into MDCK kidney epithelial cells. MDCK cells are a model system for the study of HGF-induced`scattering' and tubulogenesis (Montesano et al., 1991; Weidner et al., 1993) . Since MDCK cells are of canine origin and the nucleotidic sequence of dog HGF is not known, it is not possible to perform RT ± PCR analysis of HGF expression in these cells, which cannot therefore be ruled out. However, MDCK cells conditioned medium Figure 2 HGF is required for mutant Met-induced transformation of epithelial cells. MDCK kidney epithelial cells were transfected with the pCEV29.1 vector containing either no insert or a cDNA encoding for wild-type or mutant Met. Following selection, expression of ectopic Met was veri®ed by Western blot analysis using anti-Met antibodies (not shown). Stable transfectants were tested for their ability to form colonies in soft agar either in the presence or absence of recombinant, Baculovirusproduced human HGF (200 scatter units/ml). Cells were photographed one week after seeding. Due to the morphology of the colonies that are small and close to each other, quantitation by scoring was not possible Figure 3 Schematic representation of engineered receptors and factors used in this study. An engineered Met receptor consisting of the b-chain alone (b-Met) was obtained that is impaired in its ability to bind HGF but not to dimerize. The tyrosine couple located on the receptor tail represents the`supersite'. TK, tyrosine kinase domain. A decoy mouse Met receptor that binds and neutralizes mouse or human HGF was constructed by truncating a mouse Met at the border between the extracellular domain and the transmembrane domain. The engineered receptor is therefore secreted as a soluble protein in the medium and is not bound to the membrane. A Myc epitope was added to facilitate detection with antibodies. The consensus proteolytic sequence LRVV of HGF was mutagenized to LQVV to yield an uncleavable form of HGF. The arrow indicates the cleavage site on wild-type HGF. HL, hairpin loop; K1-4, kringles 1-4; LC, light chain (HGF b-chain) did not contain any measurable HGF activity in terms of scattering (measured on embryonic hepatocyte precursors) or Met receptor phosphorylation (data not shown).
Cells were transfected with the pCEV29.1 vector containing either mutant or wild-type Met and selected for G418 resistance. As a control, cells were also transfected with pCEV29.1 containing no insert. Resistant clones were pooled and assayed for their ability to form colonies in soft agar, either in the absence or presence of Baculovirus-produced recombinant HGF. As shown in Figure 2 , cells transfected with vector alone formed very few small colonies both in the absence and presence of HGF. Cells expressing wild-type or mutant Met also did not display signi®cative colony formation compared to the control in the absence of HGF (Figure 2, top row) . However, when HGF was added to the culture a b Figure 4 HGF binding to mutant Met is necessary for transformation and for receptor phosphorylation on tyrosine. (a) Focus forming activity of Met and b-Met, either wild-type or containing a PRC mutation, in the absence or presence of exogenous HGF. NIH3T3 cells were co-transfected with the pCEV29.1 vector containing either no insert or a cDNA encoding for Met or b-Met, together with the pBABE vector containing either no insert or human HGF. Foci were scored two weeks after transfection. Values are the mean of two experiments conducted in triplicate and the bars represent standard deviation. The left inset shows representative plates from one experiment. In the right inset, the inability of b-Met to respond to HGF is documented. NIH3T3 cells expressing Met or b-Met were deprived of serum growth factors for 24 hours and then stimulated with control medium (CTRL), with the DO24 monoclonal antibody (50 nM), or with HGF (400 scatter units/ml). Cell lysates were immuno-precipitated with antiMet antibodies, resolved by SDS ± PAGE and analysed by Western blotting using anti-phosphotyrosine antibodies (a-pTyr). The same blot was stripped and re-probed using anti-Met antibodies (a-Met) to normalize for the amount of immuno-precipitated Met protein. (b) Met protein expression and phosphorylation in cell lines obtained from the transfections described in a. Cell lysates were resolved by SDS ± PAGE and analysed by Western blotting using anti-Met antibodies (top panel). The b-Met protein migrates slightly faster than the corresponding b chain of the full size receptor (p145), most likely due to a dierent glicosylation pattern. The same lysates were immuno-precipitated with anti-Met antibodies, resolved by SDS ± PAGE, and analysed by Western blotting using anti-phosphotyrosine antibodies (bottom panel) medium, cells expressing mutant Met dramatically increased their anchorage-independent growth potential and formed numerous large colonies (Figure 2 , bottom row). Cells expressing wild-type Met also formed more colonies in the presence of ligand, although at a lower level compared to cells expressing Met PRC mutants. Western blot analysis of cell lysates using anti-Met antibodies was performed to check the expression of the ectopically expressed proteins (not shown). These data indicate that transformation of kidney epithelial cells by mutant Met requires HGF.
HGF binding to mutant Met is necessary for transformation
The Met receptor is a dimeric protein consisting of an extracellular a chain linked by a single disulphide bond with a transmembrane-spanning b chain (Comoglio, 1993) . The intracellular portion of the b chain contains the kinase catalytic region and the`supersite', responsible for receptor association with signal transducers (Ponzetto et al., 1994) . Previous work showed that a modi®ed Met receptor consisting of the b chain alone was not able to respond to HGF stimulation (Zhen et al., 1994) , suggesting that the a chain contains a domain that is indispensable for receptor interaction with the ligand.
To verify this hypothesis, a modi®ed Met receptor lacking the a chain was constructed (b-Met; Figure 3 ). The unmodi®ed (Met) or engineered (b-Met) receptors were expressed in NIH3T3 cells and tested for their ability to respond to HGF stimulation. As shown in Figure 4a , stimulation with HGF resulted in tyrosine phosphorylation of Met but not of b-Met. In contrast, stimulation with a ligand-mimetic monoclonal antibody directed against an epitope situated on the extracellular portion of the b chain of Met (DO24; Prat et al., 1998) induced phosphorylation of both Met and b-Met. Thus, although the engineered receptor b-Met expressed in NIH3T3 cells still retains the ability to dimerize and autophosphorylate by mean of a ligand-mimetic antibody, it is unable to respond to HGF stimulation. Biochemical analysis of intrinsic kinase activity revealed that the catalytic eciency of b-Met is comparable with that of Met (not shown).
To further study the role of HGF in mutant-Met mediated transformation, mutations corresponding to amino acid substitutions L1195V, D1228H or M1250T in the Met protein were introduced in the cDNA coding for b-Met and the mutant cDNAs subcloned into the pCEV29.1 vector. NIH3T3 cells were co-transfected as described above with the pCEV29.1 vector containing wild-type or mutant Met cDNA in its unmodi®ed or engineered version, together with the pBABE vector containing either no insert or human HGF cDNA. Transfected cells were used for the establishment of cell lines and for a focus forming assay as described above. All transfections yielded a similar number of colonies resistant to both G418 and puromycin. Figure 4a shows the results of the focus forming assay. None of the b-Met constructs, either wild-type or mutant, displayed focus forming activity over the background, even in the presence of exogenous HGF.
Western blot analysis revealed that all the ectopic Met proteins were expressed at similar levels ( Figure  4b ). Therefore, transformation of NIH3T3 ®broblasts by mutant Met requires receptor interaction with the ligand.
HGF is required to induce tyrosine hyper-phosphorylation of mutant Met
Since Met PRC mutations have been shown to increase the intrinsic catalytic activity and to induce constitutive tyrosine phosphorylation of the receptor (Jeers et al., 1997; Bardelli et al., 1998) , we next analysed the phosphorylation status of the mutated Met and b-Met proteins. Lysates from the cell lines obtained from the above transfection were immuno-precipitated with anti-Met antibodies, resolved by electrophoresis and analysed by Western blotting using anti-phosphotyrosine antibodies. As shown in Figure 4b , HGF increased tyrosine phosphorylation of wild-type Met and of all other mutants analysed (L1195V, D1228H and M1250T), that already displayed higher tyrosine phosphorylation. In contrast, none of the b-Met proteins were neither basally hyper-phosphorylated compared to wild-type Met nor stimulated by HGF to increase their phosphorylation status. Biochemical analysis of intrinsic kinase activity revealed that bMet mutants displayed higher catalytic activity compared to wild-type (not shown). Thus, despite higher kinase activity, mutant b-Met is not constitutively phosphorylated on tyrosine. These results indicate that not only mutant Met phosphorylation can be further increased by exogenous HGF stimulation, but also that the basal hyper-phosphorylation on tyrosine observed in Met PRC mutants depends on receptor interaction with endogenous HGF produced by NIH3T3 cells. containing the PRC mutation M1250T, were tested for their ability to form colonies in soft agar in the presence of no factor (CTRL), HGF (200 scatter units/ml) or DO24 (3 nM). Cells transfected with empty vectors were also included as a control. Due to the high amount of antibody required, the assay was performed in 24-well plates. Colonies were photographed two weeks after seeding. Scoring was not possible due to the reduced size of the well Ligand-mediated receptor dimerization is required for transformation induced by mutant Met From the previous results it emerges that receptor interaction with the ligand is necessary in order to unleash the transforming potential of mutant Met. PRC mutations increase the intrinsic catalytic activity of the kinase, but a ligand-dependent event is still required in order for the mutant receptor to become autophosphorylated on tyrosine and to mediate cell transformation. To better understand this mechanism, we tested whether arti®cial receptor dimerization induced by the ligand-mimetic monoclonal antibody DO24 (see above) could restore transformation mediated by mutant b-Met. An anchorage-independent cell growth assay was performed using NIH3T3 cells expressing the Met or b-Met proteins containing the M1250T substitution, alone or in the presence of either Baculovirus-produced recombinant HGF or the DO24 antibody. As shown in Figure 5 , the anchorageindependent growth ability of cells expressing mutant b-Met was comparable to that of the negative control even in the presence of exogenous HGF. However, addition of the DO24 antibody to the culture medium induced the same cells to dramatically increase their anchorage-independent growth ability, thus rescuing the transforming potential of mutant b-Met. Therefore, ligand-induced dimerization of the mutant receptor is a crucial event in the transforming process mediated by mutant Met.
HGF antagonists inhibit mutant Met-induced transformation of NIH3T3 cells
As mentioned above, HGF is secreted as a monomeric, inactive precursor (pro-HGF) and is processed by speci®c proteases to yield an active, dimeric ligand. Pro-HGF binds to the Met receptor, although at lower anity than mature HGF, but is not able to activate it. Thus, pro-HGF behaves as a competitive antagonist of HGF Lokker et al., 1992; Chirgadze et al., 1998) . Truncated forms of HGF have been reported to act as antagonists or partial agonists of the Met receptor (Figure 3) . The naturally occurring, alternative-spliced form NK2 has been shown to be an antagonist or a partial agonist depending on target cells and culture conditions (Chan et al., 1991; Schwall et al., 1996) . A truncated HGF that contained the a chain only (NK4) was shown to retain receptor binding without mediating biological responses Date et al., 1997 Date et al., , 1998 . Furthermore, a soluble, chimaeric form of the extracellular portion of the Met receptor has been shown to retain full HGF binding and to display neutralizing activity against HGF . By PCR techniques (see Material and methods) we obtained recombinant cDNAs encoding for NK2, NK4 and for an uncleavable form of HGF, in which the proteolytic consensus sequence LRVV was mutated to LQVV. A soluble, decoy Met receptor composed of the extracellular portion of mouse Met fused to a Myc Figure 6 Mutant Met-mediated transformation can be inhibited by HGF antagonists. NIH3T3 cells were co-transfected with the pCEV29.1 vector containing either no insert or a cDNA encoding for the M1250T Met mutant and the pBABE vector containing either no insert or a cDNA encoding for the indicated recombinant factors. Two weeks after transfection, the number of foci was determined. The percentage of inhibition or stimulation relative to the control (Met M1250T alone) was calculated after subtraction of the background. Values are the mean of three experiments conducted in triplicate and the bars indicate standard deviation. The upper right inset shows representative plates from one experiment. In the bottom left inset, ectopic Met protein expression in the various cell lines obtained from the above transfections is shown. FFA, focus forming activity; UC HGF, uncleavable HGF epitope was also constructed (Figure 3 ). This recombinant protein was shown to be eciently secreted in the medium by transfected cells and to bind recombinant mouse or human HGF in vitro (data not shown).
To test the eect of HGF antagonists on mutant Met-induced transformation we co-transfected NIH3T3 cells with the pCEV29.1 vector containing a cDNA encoding for M1250T Met together with an expression vector (pBABE) in which the cDNAs encoding for NK2, NK4, uncleavable HGF or decoy Met had been inserted. As a control, pBABE containing human HGF was also co-transfected with M1250T Met. A focus forming assay and the selection of stable transfectants were performed as described above. Figure 6 shows the results obtained in these experiments. HGF increased the focus forming ability of mutant Met by 56.3%. NK2 also increased the number of foci formed by mutant Met, although to a lower degree (6.9%), and thus behaved as a partial agonist in this system. In contrast, NK4, uncleavable HGF and decoy Met receptor inhibited mutant Met-mediated focus formation by 20.5, 45.6 and 33.9%, respectively. Transfection eciency was monitored by scoring the number of colonies resistant to both G418 and puromycin and was similar for all plates. Western blot analysis revealed that mutant Met was expressed at comparable levels in all cell lines ( Figure 6 , bottom left inset). Recombinant HGF, NK2, NK4, uncleavable HGF and decoy Met were detected in both cell extracts and conditioned media (data not shown). Similar results were obtained in anchorage-independent growth assays (not shown). These results further demonstrate that mutant Met-mediated transformation of NIH3T3 cells relies on endogenous HGF, and suggest that it is possible to block the oncogenic eect of Met PRC mutations by antagonizing HGF binding onto the mutant receptor.
Discussion
The data presented provide evidence for a pivotal role of HGF in the mediation of cell transformation induced by Met PRC mutations. This implicates that amino acid substitutions that increase the catalytic eciency of Met are not sucient by themselves to cause transformation. Importantly, a Met receptor that contains a PRC mutation but cannot bind HGF is not constitutively phosphorylated in spite of its higher kinase activity and lacks transforming potential, which can be rescued by antibody-mediated receptor dimerization. Conceivably, the major biochemical eect induced by Met PRC mutations is a decrease in the activation threshold of the kinase. However, ligand stimulation is still required to induce receptor dimerization that allows autophosphorylation on tyrosine residues, including the multifunctional`docking site' on the receptor tail that is essential for transformation (Bardelli et al., 1998) .
The requirement of HGF for the full display of the transformed phenotype induced by Met PRC mutations implies that mutant-Met mediated tumour growth in vivo relies on the availability of HGF in its active form. HGF is ubiquitously expressed by mesenchimal cells and is present in plasma and in tissue extracellular matrix as inactive, pro-HGF. Pro-HGF acts as a reservoir that is processed locally by tissues that actively utilize it and that produce high levels of extracellular proteases Miyazawa et al., 1994) . Local levels of proteases might determine signi®cant changes in the concentration of active HGF, and thus in¯uence proliferation and survival of cells bearing mutant Met. Patients carrying germ-line mutations in the Met kinase domain develop papillary renal carcinomas and in rare cases other malignancies of the stomach, rectum, lung, pancreas, breast and bile duct . Epithelial cells of the kidney produce large amounts and are the main if not the sole source of urokinase, a serine-protease that is a very thoroughly characterized pro-HGF convertase (Naldini et al., 1995) . It is conceivable that the high levels of urokinase in the kidney determine a local increment in the concentration of active HGF, that might drive mutant Met-expressing cells to form tumours. In other tissues poor in extracellular proteases, pro-HGF might even act as an inhibitor of tumour development, as suggested by our experiments.
Recalling a concept that has been recently introduced in the molecular oncology ®eld, HGF can be de®ned a`landscaper' factor that is likely to in¯uence the occurrence of a neoplastic disorder to which an inherited mutation predisposes (Kinzler and Vogelstein, 1998) . Interestingly, conversion of pro-HGF is highly induced following tissue injury, particularly in the kidney and in the liver (Miyazawa et al., 1994) . It is possible that Met PRC -transformed cells might be present in a dormant state, until a perturbing agent, physical or infectious, causes tissue injury and thus increases the local concentration of active HGF. According to this hypothesis, the possibility that Met mutations occur in other tissues subjected to injury-induced regeneration deserves some attention.
The inhibitory eect of HGF antagonists on mutant Met-induced cell transformation suggests a potential therapeutical strategy for the treatment of mutant Metrelated pathologies. For example, patients that have undergone surgical removal of a tumour that scores positive for a Met mutation could be treated with HGF-antagonizing drugs to prevent regrowth of residual cancer cells. Alternatively, the growth of benign lesions could be kept under control by HGF antagonists to prevent their malignant conversion. Interestingly, NIH3T3 cells expressing mutant Met are metastatic in experimental animals . Thus, mutant Met receptor is likely to play a role also in the invasive process of distant organ colonization by cancer cells. Drugs that antagonize HGF action on mutant Met could be therefore of desirable utility for the prevention of the metastatic spread of malignant tumours.
Materials and methods
Plasmid constructs
Reproduction of PRC mutations in the human Met cDNA was mediated by PCR as described (Bardelli et al., 1998) . Wild-type or mutant Met cDNA was subcloned into the pCEV29.1 expression vector, which carries the resistance to G418 (Michieli et al., 1996) . A cDNA encoding for human HGF (Naldini et al., 1991) with a poly-histidine tag (DDDKHHHHHHH) at the C-terminus was subcloned into the pBABE vector, which carries the resistance to puromycin (Morgernstern and Land, 1990) . Uncleavable HGF cDNA (Hartman et al., 1992) was subcloned into the pBABE vector. DNA fragments encoding for HGF NK2 and HGF NK4 corresponding to HGF amino acids 1 ± 285 and 1 ± 495, respectively (numbering according to Gene Bank #M73239; Weidner et al., 1991) , were obtained by standard PCR techniques and subcloned into the pBABE vector. The cDNA encoding for decoy Met was obtained by RT ± PCR using mouse liver total RNA as template and an oligonucleotide pair corresponding to amino acids 1 ± 929 of mouse Met (Gene Bank #Y00671; Chan et al., 1988) . The 3' oligonucleotide contained a sequence encoding for the Myc epitope EQKLISEEDL. The ampli®ed fragment was subcloned into the pBABE vector. The resulting fusion protein was immunoreactive with anti-Myc monoclonal antibody clone 9E10 (Calbiochem). The cDNA encoding b-Met (Zhen et al., 1994) was obtained by standard PCR techniques by deleting the nucleotides corresponding to amino acids 33 ± 307 of human Met (Gene Bank #X54559; Ponzetto et al., 1991) and was subcloned into the pCEV29.1 vector. Thus the engineered protein maintained the original leader sequence of the parental Met.
Cells, transfections and transformation assays
NIH3T3 cells were cultured in Dulbecco's Modi®ed Eagle Medium (DMEM) containing 10% heat inactivated calf serum (HICS; Colorado Serum Company). Transfections were carried out by the calcium phosphate method as described (Michieli et al., 1996) using 40 mg of carrier DNA (calf thymus high molecular weight DNA; Boehringer Mannheim) per 100 mm plate. Each plate was transfected with 2 mg of the pCEV29.1 vector containing either no insert or a cDNA encoding for a Met protein (wild-type or mutant, Met or b-Met) and 4 mg of the pBABE vector containing either no insert or a cDNA encoding for HGF, uncleavable HGF, HGF NK4, HGF NK2, or decoy Met. Two days after transfection, cells were split into four plates; three plates were cultured in DMEM containing 5% HICS and were used for measuring focus formation, and the fourth was cultured in DMEM containing 10% HCS and the appropriate selective drugs (G418, 750 mg/ml; puromycin 1 mg/ml) to establish stable transfectants. Foci were scored two weeks after transfection following ®xation with para-phormaldehyde and Giemsa staining. Clones resistant to G418 and puromycin were pooled and used for Western blot analysis and/or soft agar assays. MDCK cells were cultured in DMEM containing 10% foetal bovine serum (FBS) and transfected by the calcium phosphate method using 40 mg of carrier DNA and 5 mg of the appropriate plasmid per 100 mm plate. Selection of stable transfectants was performed in DMEM containing 10% FBS and 750 mg/ml G418. Analysis of colony formation in soft agar was performed as described (Michieli et al., 1996) . Brie¯y, NIH3T3 or MDCK cells were diluted to a concentration of 25 000 cells/ml in DMEM containing 10% HICS or FBS, 0.5% Seaplaque agar and the appropriate factor or antibody (when applicable). Cells were seeded in 6-well plates (2 ml/ well) or 24-well plates (0.5 ml/well) containing a 1% agar underlay and supplemented once a week with DMEM containing 10% HICS or FBS. When applicable, Baculovirus-produced recombinant HGF (Gaudino et al., 1994) or the DO24 antibody were added three times a week (HGF, 200 scatter units/ml; DO24, 3 nM). Colonies were photographed and/or scored one week (MDCK) or two weeks (NIH3T3) after seeding.
Immunological reagents
The Met protein was immuno-precipitated with a monoclonal antibody (DQ13; Crepaldi et al., 1994) and detected by Western blotting with polyclonal antibodies (C-28, Santa Cruz Biotechnology). Anti-phosphotyrosine antibodies were purchased from UBI. Anti-HGF polyclonal antibodies were obtained by immunizing rabbits with human recombinant HGF. The DO24 monoclonal antibody has been described previously (Prat et al., 1998 The breast cancer susceptibility gene BRCA2 is expressed in a wide range of tissues as an 11-kb mRNA transcript that encodes a 3418-amino acid protein involved in the response to DNA damage. To obtain better a molecular characterization of BRCA2 expression in sporadic breast cancer, we quanti®ed BRCA2 mRNA by means of RT ± PCR in a large series of human primary breast tumours. BRCA2 expression showed wide variations in tumour tissues, being underexpressed in 14/127 (11%) and overexpressed in 25/127 (20%). BRCA2 overexpression (but not underexpression) correlated signi®cantly with Scar, Bloom and Richardson (SBR) histopathological grade III (P=0.007) and was mainly attributed to nuclear polymorphism (P=0.005) and mitotic index (P=0.048), suggesting that the BRCA2 gene contributes to the proliferation rate in breast tumours. BRCA2 status (under and/or overexpression versus normal expression) was not associated with subsequent relapse and with signi®cantly shorter disease-free survival. The observed disruption of BRCA2 expression is not due to allelic loss, because the latter did not correlate with altered BRCA2 mRNA expression in our tumour series. Taken together, these data suggest the involvement, especially by overexpression, of the BRCA2 gene in sporadic breast tumours, and the existence of another important tumour-suppressor gene in breast cancer, in the 13q12-q13 region.
Keywords: breast carcinoma; BRCA2; quantitative RT ± PCR Introduction Breast cancer, one of the most common life-threatening diseases in women, occurs in hereditary and sporadic forms. The two major breast cancer susceptibility genes, BRCA1 and BRCA2, have recently been isolated (Miki et al., 1994; Wooster et al., 1995) . Both behave as classical tumour-suppressor genes, loss of both alleles being required for malignancy. Recent studies provide a role for BRCA1 and BRCA2 proteins in response to DNA damage, by interaction with RAD51, a protein involved in the repair of doublestrand DNA breaks, as well as in mitotic and meiotic recombination (Zhang et al., 1998) . A number of germline mutations in the BRCA1 and BRCA2 genes have been identi®ed in families prone to breast cancer (Shattuck-Eidens et al., 1995; Couch et al., 1996; Phelan et al., 1996) .
BRCA2, like BRCA1, is not frequently mutated in sporadic breast cancers (Lancaster et al., 1996; Miki et al., 1996; Teng et al., 1996) . However, high frequencies of loss of heterozygosity (LOH) on 17q12-q21 and 13q12-q13 (sites of BRCA1 and BRCA2) (CletonJansen et al., 1995; Kerangueven et al., 1995; Beckmann et al., 1996; Hamann et al., 1996; Kelsell et al., 1996; BieÁ che et al., 1997) point to a signi®cant role or these two genes in the genesis of sporadic breast cancer, through a mechanism other than structural mutation. LOH at BRCA2 was found to be an independent prognostic factor (Van Den Berg et al., 1996) . Such sporadic involvement is also convincing in regard to the BRCA1 results of Thompson et al. (1995) which showed down-regulation of BRCA1 mRNA levels in tumours relative to normal breast epithelial cells.
To clarify the signi®cance of the BRCA2 gene in the development of sporadic breast cancer, we quanti®ed BRCA2 gene expression by means of competitive RT ± PCR in a series of 127 unilateral invasive primary breast tumours. We also determined whether alterations of BRCA2 expression correlate with LOH at the BRCA2 locus.
Results
BRCA2 mRNA expression in normal breast tissues
To determine the cut-o point for altered BRCA2 expression in breast cancer tissue, the N BRCA2 value, calculated as described in Materials and methods, was determined for 16 normal breast RNA samples. As this value consistently fell between 0.6 and 1.6 (mean 0.94+0.21), values of 2 or more were considered to represent overexpression, and values of 0.5 or less underexpression, of BRCA2 mRNA.
BRCA2 mRNA expression in tumour breast tissues
Among the 127 breast tumour RNA samples tested, 39 (31%) showed altered BRCA2 mRNA expression. Fourteen tumours (11%) showed underexpression of BRCA2 mRNA (N BRCA2 from 0.1 ± 0.4) and 25 (20%) showed overexpression (N BRCA2 from 2.2 ± 13). Figure 1 represent data on tumours in which the BRCA2 gene was overexpressed (BRCA07, N BRCA2 =4.44), expressed normally (BRCA76, N BRCA2 =1.06) and underexpressed (BRCA43, N BRCA2 =0.16). The BRCA2 primer pair used *Correspondence: R Lidereau Received 29 January 1999; revised 14 April 1999; accepted 14 Aprilin this study was placed in the 3'-terminal region (exons 24 ± 26) of the BRCA2 gene; similar results were obtained with a second BRCA2 primer pair in the 5'-region (exons 3 ± 5) in 30 of the 127 breast tumours analysed in this study (data not shown).
Correlation between BRCA2 mRNA levels and clinical and pathological parameters
We sought links between BRCA2 mRNA level status and standard clinicopathological and biological factors in breast cancer (Table 1 ). The only statistically signi®cant association was between BRCA2 mRNA overexpression and histopathological grade III (P=0.007). Sixty per cent (15/25) of tumours with overexpression of BRCA2 were histopathological grade III, compared to 30.8% (4/13) of those with underexpression and 30.9% (25/81) of those with normal expression of BRCA2.
Histoprognostic grade is a combination of three criteria: tubular dierentiation, nuclear polymorphism, and mitotic index. We therefore also tested these three components in relation to the BRCA2 mRNA level ( Table 2 ). The prevalence of histopathological grade III in the BRCA2 mRNA overexpressed tumours was attributable to nuclear polymorphism (P=0.005) and mitotic index (P=0.048), but not to tubular differentiation.
Moreover, patients with tumours overexpressing and/or underexpressing BRCA2 did not relapse more frequently (Table 1 ) and did not have signi®cantly shorter disease-free survival after surgery (log-rank test), compared to patients with tumours normally expressing BRCA2. Figure 1 Representative results of BRCA2 expression in human breast tissues by means of quantitative RT ± PCR. Peaks BRCA2 (or TBP) and BRCA2 QDS (or TBP QDS ) represent the PCR products of the BRCA2 cDNA (or TBP) and of its corresponding quantitative DNA standard' (QDS). The area of each peak correlates with the amount of PCR product. For each tumour sample, the BRCA2 cDNA peak area value (BRCA2) was divided by the BRCA2 QDS peak area value (BRCA2 QDS ) to obtain a BRCA2 mRNA amount value (BRCA2/BRCA2 QDS ) which was next divided by the TBP mRNA amount value (TBP/TBP QDS ) to obtain the ®nal BRCA2 (normalized) value. This value was equal to 4.44 in tumour BRCA07, 1.06 in tumour BRCA76 and 0.16 in tumour BRCA43
BRCA2 overexpression in breast carcinomas by RT ± PCR I Bie Á che et al Relationship between BRCA2 mRNA levels and 13q12-q13 LOH The 127 tumours studied for BRCA2 expression had also been tested for LOH at four polymorphic DNA marker loci¯anking BRCA2 (D13S289, D13S260, D13S171, D13S267). All patients were informative for one or more loci on 13q12-q13. LOH was found in 44.1% (56/127) of the tumour DNAs, while the remainder had a normal pro®le. As shown in Table  3 , we found no link between 13q12-q13 LOH and BRCA2 mRNA overexpression, underexpression or both.
Discussion
Germ-line mutations of the two breast cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for approximately 50 and 20% of hereditary breast cancers, respectively. The supposition that BRCA2 is a tumour-suppressor gene is supported by the observation that most breast tumours arising in patients with germ-line BRCA2 mutations exhibit LOH at the BRCA2 locus, typically involving loss of the wild-type BRCA2 allele (Collins et al., 1995; Gudmundsson et al., 1995) . However, similar to the failure to ®nd BRCA1 mutations in sporadic breast cancers, only a small percentage of sporadic breast tumours appear to carry somatic mutations in the BRCA2 gene despite the fact that 30 ± 40% of sporadic breast cancers show LOH at this locus (Cleton-Jansen et al., 1995; Kerangueven et al., 1995; Beckmann et al., 1996; Hamann et al., 1996; Kelsell et al., 1996; BieÁ che et al., 1997) . It is possible that DNA lesions not detectable by standard mutation screening may be responsible for disrupting the function of BRCA2 in sporadic tumours. Little is known about BRCA2 gene expression, except that BRCA2 mRNA has a tissue-speci®c expression pattern similar to that of BRCA1 mRNA and that these two genes are coordinately regulated during mammary epithelial proliferation and dierentiation, despite the fact that they display no homology (Rajan et al., 1997) . To ®nd out more about BRCA2 mRNA expression in sporadic breast cancer, we quanti®ed BRCA2 gene expression by means of competitive RT ± PCR in a series of 127 unilateral invasive primary breast tumours. Surprisingly, we observed both underexpression (11%) and overexpression (20%) of BRCA2 mRNA. Interestingly, a signi®cant link was observed between BRCA2 mRNA overexpression and tumours of histopathological grade III (P=0.007), suggesting that overexpression of BRCA2 plays a role in the aggressiveness of breast tumours. The prevalence of histopathological grade III in the BRCA2 mRNA overexpressed tumours was mainly attributed to nuclear polymorphism and mitotic index, which respectively re¯ect extent of genetic changes in tumours and the proliferation rate. These results obtained in vivo are thus in agreement with reports from several authors (Rajan et al., 1996; Vaughn et al., 1996) showing that BRCA2 mRNA expression is up-regulated in rapidly proliferating cells in vitro. These observations are consistent with a model in which BRCA2 exerts a positive eect on proliferation. Such a model is dicult to reconcile with the genetic evidence that BRCA2 is a tumour-suppressor gene whose overexpression should inhibit proliferation and vice versa. Rajan et al. (1997) We observed no link between BRCA2 expression status and steroid-receptor status, although it has previously been shown that mRNA BRCA1 and BRCA2 expression is up-regulated by estrogen in human breast cancer cell lines (Spillman and Bowcock, 1996) . However, it has also been shown that the upregulation of BRCA1 mRNA expression by ovarian hormones in the mouse mammary gland is signi®cantly greater than that of BRCA2 (Rajan et al., 1997) .
We also clearly identi®ed 14 tumours with underexpressed BRCA2 mRNA. This subset of breast tumours, where no prevalence of histological grade III was observed, is distinct from the group with BRCA2 overexpression. It has been shown that BRCA2 may play a part in monitoring genomic integrity and in DNA repair. Low expression of BRCA2 mRNA could thus be the cause of the genetic instability observed in human breast tumours. This hypothesis should be tested in a larger group of tumours with BRCA2 underexpression, by studying genetic instability (as measured in terms of gene ampli®cations and LOHs).
Disruption of expression of BRCA2 mRNA observed in this series of sporadic breast tumours was not due to the loss of one BRCA2 allele, we failed to observe any link between LOH at BRCA2 and altered BRCA2 mRNA expression, suggesting that LOH did not aect the level of BRCA2 mRNA. This result raises two points. (a) BRCA2, in sporadic breast tumours, does not seem to act as a classical tumoursuppressor gene that is inactivated when both alleles acquire alterations (somatic mutations and/or allele loss, typically through deletion). It is important to note that the promoter of BRCA2 showed absence of methylation of CpG dinucleotides in breast tumours (Collins et al., 1997) , suggesting that this alternative mechanism of tumour-suppressor-gene inactivation by transcriptional regulation of mRNA expression is unlikely to explain the dierences in BRCA2 mRNA expression observed in this study; (b) the BRCA2 gene itself is not the main target gene of the high level (44% in this study) of LOH at 13q12-q13 in breast cancer. This raises the possibility that another key tumoursuppressor gene in this region plays an important role in breast cancer. In conclusion, this study suggests that the BRCA2 gene is involved in sporadic breast cancer, especially in cell proliferation. Our ®ndings should be con®rmed at the protein level when suitable antibodies become available. Further studies are also necessary to elucidate the genetic (or epigenetic) mechanism responsible for the observed dysregulation of BRCA2 mRNA expression.
Materials and methods
Patients and samples
We analysed tissue from excised primary breast tumours from 127 women treated at the Centre ReneÂ Huguenin from 1977 to 1989. The samples were examined histologically for the presence of tumour cells. A tumour sample was considered suitable for this study if the proportion of tumour cells was more than 60%. Immediately following surgery the tumour samples were stored in liquid nitrogen until extraction of RNA and high-molecular-weight DNA.
The patients (mean age 58 years, range 34 ± 91) met the following criteria: primary unilateral non-metastatic breast carcinoma on which complete clinical, histological and biological data were available; and no radiotherapy or chemotherapy before surgery. The main classifying prognostic factors are presented in Table 4 . The median follow-up was 8.9 years (range 0.2 ± 16.2). Forty-®ve patients relapsed (distrubution of ®rst relapse events among patients was as follows: 13 local and/or regional recurrences, 28 metastases, and four both).
Specimens of adjacent normal breast tissue were taken from seven breast cancer patients, and normal breast tissue was obtained from eight women undergoing cosmetic breast surgery, as a source of normal RNA. Total RNA from a pool of six normal human breast tissue samples was also purchased from Clontech.
Peripheral blood leukocytes were used as a source of normal DNA for each patient.
Evaluation of`classical' prognostic factors
The histological type and steroid-hormone receptor status of each tumour, and the number of positive axillary nodes, were established at the time of surgery. The malignancy of in®ltrating carcinomas was scored according to Bloom and Richardson's (1957) histoprognostic system. Estrogen and progesterone receptor status was assayed as described by the European Organisation for Research and Treatment for Cancer (EORTC, 1980) , with a detection threshold of 10 fmol/mg cytosolic protein.
RNA analysis
A quantitative RT ± PCR method was used to examine BRCA2 mRNA expression. The precise amount of total RNA added to each reaction (based on optical density) and its quality (i.e. lack of extensive degradation) are both dicult to assess. We therefore also quanti®ed the transcripts of TBP (a component of the transcription factor TFIID) as the endogenous mRNA control, and each sample was normalized on the basis of its TBP content. We selected the TBP gene as an endogenous control because the prevalence of its transcripts is similar to that of the BRCA2 target gene, and because there are no known TBP retropseudogenes. (Retropseudogenes lead to co-amplification of contaminating genomic DNA and thus interfere with RT ± PCR, despite the use of primers in separate exons). We therefore rejected the b-actin, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and HPRT (hypoxanthine phosphoribosyltransferase) genes as endogenous controls because of the existence of corresponding retropseudogenes (Dirnhofer et al., 1995; Sellner and Turbett, 1996) ; we also rejected the human 18S rRNA gene, which is intronless and has very high abundance of transcripts; and the b2-microglobulin gene whose expression seems altered in some tumours (Mullen, 1998) .
RNA extraction
Total RNA was extracted from breast specimens by the acid-phenol guanidium method (Chomczynski and Sacchi, 1987) . The quality of the RNA samples was determined by electrophoresis through denaturing agarose gels and staining with ethidium bromide, and the 18S and 28S RNA bands were visualized under ultraviolet light. The yield was quanti®ed spectrophotometrically in a 50 ml microcuvette.
cDNA synthesis RNA was reverse transcribed in a ®nal volume of 20 ml containing 16 RT ± PCR buer (1 mM each dNTP, 5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl pH 8.3), 20 units of RNase inhibitor, 50 units of Moloney Murine Leukaemia Virus reverse transcriptase (Perkin-Elmer), 2.5 mM random hexamers and 1 mg of total RNA. The samples were incubated at 208C for 10 min and 428C for 30 min, and reverse transcriptase was inactivated by heating at 998C for 5 min and cooling at 58C for 5 min. The volume was then made up to 200 ml with 16 RT ± PCR buer, yielding the RT mix used for PCR. Ten microliters (1/20 of RT-mix) was used for subsequent PCR.
Primers
Primer pairs for quantitative RT ± PCR were chosen with the assistance of the Oligo 4.0 (National Biosciences) computer program and by performing BLASTN searches against dbEST and nr (the non redundant set of GenBank, EMBL and DDBJ database sequences) to con®rm the total gene speci®city of the nucleotide sequences chosen for the primers and the absence of polymorphisms.
BRCA2-speci®c primers used for PCR ampli®cation were the following: BRCA2-9469U (5'-GTTGTGAAAAAAA-CAGGACTTG-3') and BRCA2-9821L (5'-CAGTCTT-TAGTTGGGGTGGA-3'); the BRCA2-speci®c product size corresponds to 353 bp. Primers speci®c for ampli®cation of a 260-bp product of the TBP gene were TBP-750U (5'-ACAGGAGCCAAGAGTGAAGAA-3') and TBP-1009L (5'-CCAGAAACAAAAATAAGGAGA-3').
Primers are designated by the nucleotide position (relative to BRCA2 GenBank #U43746 and TBP GenBank # X54993) corresponding to the 5' position, followed by the letter U for upper (sense strand) or L for lower (antisense strand). To avoid ampli®cation of contaminating genomic DNA, one of the two primers was placed at the junction between two exons or in a dierent exon. For example, the upper primer of BRCA2 (9469U) was placed at the junction between exons 24 and 25, whereas the lower primer (9821L) was placed in exon 26. One member of each primer pair was labeled with¯uorescein at the 5' end by using the¯uoro-prime method.
BRCA2 mRNA steady-state level
To take into account PCR variability, quantitative RT ± PCR is based on co-ampli®cation of speci®c cDNA with à quantitative DNA standard' (QDS), using the same two primers (Foley et al., 1993; Pannetier et al., 1993) . Speci®c QDS were generated by PCR using the`looped oligo' method (Sarkar and Bolander, 1994) , with creation of a 12-bp insert in the PCR product sequence for each test gene (BRCA2 or TBP), as described by Lazar et al. (1995) . With this procedure, target cDNA and QDS yield labelled PCR products of dierent sizes, which we identi®ed by using a DNA sequencer. Gene mRNA values were expressed as a ratio between the target cDNA and its corresponding QDS. Ampli®cation eciency between target cDNA and QDS during exponential and non-exponential phases was checked. According to Pannetier et al. (1993) , the ratios between the target cDNA and its QDS are similar whatever the number of cycles.
For each PCR run, a master mix was prepared on ice with 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl pH 8.3, 400 nM each primer, a known quantity of the corresponding QDS and one unit of AmpliTaq DNA polymerase (Perkin Elmer). The amount of QDS was selected for each target cDNA so as to obtain similar¯uorescence intensities for standard and corresponding cDNA-derived PCR products. Ten microliters of RT-mix for each sample was added to 40 ml of the master mix on ice. The PCR consisted of an initial denaturation step at 948C for 5 min and 30 (BRCA2) or 32 cycles (TBP) of 30 s at 948C, 30 s at 608C, 45 s at 728C, and a ®nal extension step of 10 min at 728C, using a Perkin-Elmer 9600 DNA thermocycler.
PCR products were diluted tenfold and 2.5-ml aliquots of each were added to 2.5 ml of deionized formamide containing 0.3 ml of a molecular size marker (Genescan 500 ROX, Perkin Elmer). The mixtures were denatured by heating and 2.5 ml aliquots of each were loaded onto 6% polyacrylamide/8 M urea gel and run in the sequencer for 6 h at 1200 V. The dierent fragments were quanti®ed with Genescan 672 Fragment Analysis software (Perkin Elmer), which calculates the size and area under the peaks. PCR products of target cDNA and corresponding QDS give two dierent¯uorescence peaks. The area under each peak, expressed in relative¯uorescence units (RFU), correlates with the amount of PCR product. Results are expressed as a ratio between target cDNA RFU and its corresponding QDS RFU.
Quantitation was based on the determination of the relative amount of the BRCA2 target message to the TBP endogenous control to normalize the amount and quality of total RNA. Final results, expressed as N-fold dierences in BRCA2 gene expression relative to TBP gene expression, termed`N BRCA2 ', were determined as follows:
The reproducibility of the quantitative measurements was evaluated by conducting independent replicate cDNA synthesis and PCR reactions.
DNA analysis
DNA was extracted from frozen tumour tissue and blood leukocytes of each patient by using standard methods (Maniatis et al., 1982) . The carcinomas were screened with four polymorphic microsatellite DNA marker loci¯anking BRCA2 (D13S289, D13S260, D13S171, D13S267) to identify all patients for LOH BRCA2 status.
The PCR was run in a total volume of 50 ml, with 50 ng of genomic DNA, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl pH 8.3, 400 nM each primer, 200 mM each dNTP and one unit of AmpliTaq DNA polymerase (Perkin Elmer). Microsatellite markers were assayed by PCR ampli®cation of genomic DNA. The annealing temperature, number of ampli®cation cycles and extension time were adapted to each primer set. One microliter of product was mixed with 3 ml of denaturing loading buer and denatured by heating; then 1.5-ml aliquots of each sample were loaded onto 6% acrylamide gels containing 7.5 M urea. DNA was transferred to nylon membrane ®lters. The CA repeat probe was labelled with 32 PdCTP by using terminal deoxynucleotidyl transferase. The membrane ®lters were hybridized overnight at 428C with the labelled probe, then washed, and autoradiographed at 7808C for an appropriate time.
Normal DNA samples which were polymorphic at a given locus were considered`informative', whereas homozygotes were considered`uninformative'. Only cases of constitutional heterozygosity were used in the evaluation of LOH. The signal intensity of the polymorphic alleles was determined by visual examination (three observers) and con®rmed by densitometry. The results of all scanned samples were in direct agreement with the initial visual scoring. LOH was considered to occur when the intensity of the allele in tumor DNA was less than 40% of that in corresponding normaltissue DNA (peripheral blood lymphocytes). LOH was partial in most cases, the band being fainter than the conserved allele but still visible. Such partial losses are due either to contaminating normal tissue or to tumor heterogeneity.
Statistical analysis
Disease-free survival (DFS) was determined as the interval between diagnosis and detection of the ®rst relapses (local and/or regional recurrences, and/or metastases). Clinical, histological and biological parameters were compared using the chi-square test. Dierences between the two populations were judged signi®cant at con®dence levels greater than 95% (P50.05). Survival distributions were estimated by the Kaplan-Meier method (Kaplan and Meier, 1958) , and the signi®cance of dierences between survival rates was ascertained using the log-rank test (Peto et al., 1977) .
SHORT REPORT
The retinoblastoma tumor suppressor inhibits cellular proliferation through two distinct mechanisms: inhibition of cell cycle progression and induction of cell death Studies aimed at examining the precise function(s) of the retinoblastoma tumor suppressor protein, RB, have been hindered by the rapid phosphorylation and inactivation of ectopically expressed RB which occurs in the majority of cell types. Therefore, ectopically expressed RB is a poor inhibitor of cellular proliferation. We have designed constitutively active RB proteins, PSM-RB, that cannot be inactivated by phosphorylation. Using these proteins, we show that unlike wild-type RB, PSM-RB proteins inhibit cell cycle progression in a broad range of tumor cell types. Furthermore, unlike p16 ink4a , PSM-RB is also a potent inhibitor of cell cycle progression in RB-de®cient tumor cells. Surprisingly, we identi®ed a tumor cell line that is resistant to the cell cycle inhibitory eects of PSM-RB. This ®nding challenges the hypothesis that RB must be inactivated in all cells for cell cycle progression to occur. Further characterization of this`resistant' tumor line revealed that proliferation of these cells is still inhibited by PSM-RB. We show that this is due to PSM-RB-induced cell death. As such, these studies are the ®rst to show that RB inhibits cellular proliferation through at least two distinct mechanisms ± inhibition of cell cycle progression and induction of cell death.
Keywords: apoptosis; cyclin; phosphorylation; cell death; RB The retinoblastoma tumor suppressor protein, RB, is inactivated in over 60% of studied human tumors (Bartek et al., 1997; Sherr, 1996) . Inactivation of RB can be achieved through multiple distinct mechanisms, including direct loss of functional protein due to mutation, binding of oncoproteins of DNA tumor viruses, or by overt phosphorylation of RB, which inactivates its growth-suppressing function (Bartek et al., 1997; Sherr, 1996; Wang et al., 1994) . It has been hypothesized that RB must be phosphorylated and inactivated by cyclin dependent kinase (CDK)/cyclin complexes in cells to allow for cell cycle progression, and in tumor cells this process is often deregulated (Bartek et al., 1997; Sherr, 1996) . For example, ampli®cation of the proto-oncogenes CDK4 or Cyclin D1 results in excessive phosphorylation and inactivation of RB. Likewise, loss of the tumor suppressor protein p16 ink4a which normally serves to attenuate the activity of CDK4 and cyclin D1, results in deregulated phosphorylation and inactivation of RB. It is thought that unphosphorylated (i.e. active) RB prevents cellular proliferation by sequestering a host of factors and assembling complexes which inhibit cell cycle progression (De Pinho, 1998; Sidle et al., 1996; Wang et al., 1994) . Phosphorylation of RB by CDK/cyclin complexes causes release of these proteins, and thus enables cell cycle advancement.
Studies aimed at directly de®ning the role of RB in cell cycle processes have been hindered by the fact that ectopically expressed wild-type RB is a very poor inhibitor of cellular proliferation, since it is phosphorylated and inactivated by endogenous CDK/Cyclin activity (Wang et al., 1994; Zacksenhaus et al., 1993) . Because of this, the majority of studies on wild-type RB have been carried out in one cell line, the osteosarcoma-derived SAOS-2, which fails to phosphorylate ectopically expressed wild-type RB (Qin et al., 1992; Templeton et al., 1991) . We have circumvented the problem of RB inactivation/phosphorylation by constructing a series of phosphorylation-site mutated RB proteins (PSM-RB), which cannot be inactivated by phosphorylation (Knudsen et al., 1998a; Knudsen and Wang, 1997) . These proteins are predicted to be constitutively active for growth suppression. In this report, we tested the ability of PSM-RB to inhibit the proliferation of a large number of tumor cell lines. Surprisingly, these studies revealed that RB inhibits cellular proliferation through at least two distinct mechanisms, one via cell cycle arrest and one via cell death.
It has been proposed that phosphorylation of RB is a requirement for cell cycle progression and that a blockade of RB phosphorylation will universally inhibit cell cycle progression (Bartek et al., 1997; Sherr, 1996; Sidle et al., 1996; Weinberg, 1995) . To test this hypothesis, we monitored the action of our PSM-RB proteins on cell cycle progression in seven tumor cell lines which contain functional endogenous RB. To monitor the in¯uence of PSM-RB (or other eectors) on cell cycle progression we co-transfected tumor cell lines with a green¯uorescent protein expression plasmid and plasmids encoding either vector, wild-type RB (WT-LP), p16 ink4a or PSM-RB (PSM.7-LP). The cells were then labeled with bromodeoxyuridine (BrdU) and the incorporation of BrdU in the transfected (GFP-positive) cells was detected by indirect immuno¯uorescence staining, as previously described (Knudsen et al., 1998a) . In the majority of these tumor cell lines wild-type RB had only a limited eect on BrdU incorporation, maximally reducing BrdU incorporation by approximately 1.5-fold ( Figure  1a ). This ®nding is consistent with prior results which demonstrate that wild-type RB is a weak inhibitor of cell cycle progression, since the protein is rapidly inactivated by endogenous CDK/cyclins (Wang et al., 1994; Zacksenhaus et al., 1993) . In contrast PSM-RB was a very potent inhibitor of cell cycle progression, inhibiting the incorporation of BrdU by a 3 ± 11-fold dependent on cell line, similar to the action of p16 ink4a which is known to arrest tumor cell lines expressing functional endogenous RB (Lukas et al., 1995) (Figure  1a ). These results support the hypothesis that even in tumor cells, phosphorylation and inactivation of RB is required for cell cycle progression.
A number of RB-de®cient tumor cell lines have been identi®ed. Some of these are known to be inhibited by wild-type RB (e.g. SAOS-2), whereas others are resistant to the ectopic expression of RB. Again, this resistance has been postulated to be due to phosphorylation and inactivation of the ectopically expressed RB in these cells. As expected, we observed that cell cycle progression of SAOS-2 cells was arrested by both wildtype RB and PSM-RB (Figure 1b) . The small cell lung cancer cell lines H69 and H209 were also cell cycle inhibited by PSM-RB, as indicated by the signi®cant inhibition of BrdU incorporation (Figure 1b) . Consistent with these observations, it has been shown that another RB mutant resistant to CDK-mediated phosphorylation causes G1 delay in RB-defective 5637 cells (Antelman et al., 1997) . Since these cell lines are all de®cient for endogenous RB, we ®nd that they are resistant to the in¯uence of the p16 ink4a tumor suppressor protein (Figure 1b) . Therefore, unlike p16 ink4a PSM-RB acts to inhibit the cell cycle of RB-de®cient cells.
In general, phosphorylation of RB has been viewed as a requirement for cell cycle progression. This idea comes from the ®nding in multiple systems that dephosphorylation of RB both correlates with and is causative for cell cycle arrest (Bartek et al., 1997; Sherr, 1996; Wang et al., 1994) . Surprisingly, we ®nd that C-33A tumor cells progress through the cell cycle in the presence of constitutively active PSM-RB ( Figure 1b) . As shown in Figure 1b , C33-A (HPVnegative cervical carcinoma) cells readily incorporate BrdU in the presence of PSM-RB. Analysis of transfected C33-A cells by¯ow cytometry revealed that PSM-RB had no eect on cell cycle distribution (not shown). Continued cell cycle progression was also observed in C33-A cells transfected with other PSM-RB proteins (PSM.11-RB) and with the combined transfection of wild-type RB and p16 ink4a (not shown). These data challenge the notion that inactivation of RB is required for cell cycle progression in all cells. Interestingly, C33-A cells are RB-de®cient, and it has been previously shown that wild-type RB fails to inhibit the cell cycle in C33-A cells (Zhu et al., 1993) . This had been hypothesized to be due to the phosphorylation of RB in these cells by endogenous CDK/cyclin activity. However, our ®ndings suggest instead that the pathways through which RB functions to impinge on the cell cycle are short-circuited in these cells. Since C33-A cells have been used previously to study RB biochemical activity (Knudsen and Wang, 1997; Whitaker et al., 1998) , we focused on elucidating how these cells bypass the requirement of RB inactivation for cell cycle progression.
To determine how C33-A cells bypass the requirement of RB phosphorylation for cell cycle progression we investigated the behavior of C33-A cells expressing PSM-RB. To carry out these experiments, C33-A cells were co-transfected with vector or PSM-RB expression plasmids and a plasmid encoding puromycin resistance. Transfected cells were then subjected to rapid puromycin selection. Following 48 h of selection, all untransfected C33-A cells were killed (not shown). Transfected cells surviving such a selection procedure were harvested and used for biochemical analysis, as previously described (Knudsen et al., 1998a) . Initially, we investigated the expression of the transfected PSM-RB protein in either C33-A cells, which progress through the cell cycle in the presence of PSM-RB, or in U20S cells, which arrest in response to PSM-RB. We clearly observed the full-length PSM-RB protein in the U20S (arrested) cells (Figure 2a, lane 4) . By contrast, a predominantly cleaved form of PSM-RB (pPSM-D) was observed in the selected C33-A cells (Figure 2a, lane 2) . In transiently transfected C33-A cells (24 h posttransfection) this form of PSM-RB was present, but not predominant (Knudsen and Wang, 1997) . The size of this cleaved fragment of RB is consistent with the cleavage of RB caused by caspases, enzymes germane to the process of programmed cell death (Wang, 1997) .
To determine the eect of PSM-RB expression on cell cycle targets of RB, we analysed the expression of cyclin A in both the PSM-RB-arrested U20S cells, and in the PSM-RB transfected C33-A cells, which were progressing through the cell cycle. Cyclin A was used as a reporter for RB function, since we have previously shown the cyclin A is down-regulated as a consequence of PSM-RB mediated cell cycle arrest (Knudsen et al., 1998a) . We found that cyclin A expression was not down-regulated in the C33-A cells as a consequence of PSM-RB expression (Figure 2b, lanes 1 and 2) . In contrast, in the U20S cells, cyclin A expression was signi®cantly reduced. Thus, PSM-RB inhibits the expression of cyclin A concomitant with the inhibition of cell cycle progression. Presumably in C33-A cells the pathway through which RB acts to inhibit the expression of cyclin A is compromised.
We attempted to expand these rapidly selected cells and establish stable cell lines of C33-A cells expressing PSM-RB, albeit cleaved. Following selection and a total of 8 days in culture, C33-A cells transfected with vector gave rise to numerous colonies (Figure 2c ). However, there was a dramatic reduction in colony number of cells transfected with PSM-RB, relative to those transfected with vector alone (Figure 2c) . Importantly, this result suggests that although PSM-RB does not inhibit cell cycle progression in C33-A cells, it does inhibit cellular proliferation. Consistent with this idea, when we attempted to isolate individual clones expressing PSM-RB we found that none of the isolated clones expressed even the cleaved form of PSM-RB (Figure 1d ). The ®ndings that: (i) the PSM-RB protein is cleaved; and (ii) there is a net inhibition of proliferation without in¯uence of cell cycle progression, suggested that PSM-RB may be inducing cell death in C33-A cells.
To determine how PSM-RB inhibits C33-A proliferation we followed the behavior of C33-A cells transfected with PSM-RB or a small C-terminal fragment of RB (7S-SE) which has no activity (Whitaker et al., 1998) . To monitor those cells transfected with RB we used an antibody directed against the C-terminal of RB for direct immunofluorescence (851) (Welch and Wang, 1993) . In doing so we followed those cells expressing ectopically expressed RB over an extended period. At 48 h following transfection, PSM-RB did not in¯uence BrdU incorporation and the morphology of the RB-positive cells was similar to the untransfected or 7S-SE transfected cells (Figure 3b, and not shown) . However, at 120 h post-transfection a large percentage of the PSM-RB- Figure 1 Cell cycle inhibition by PSM-RB. The indicated cell lines were co-transfected with a GFP-expression plasmid and the indicated plasmids (vector, p16 ink4a WT-RB, or PSM-RB). All cells except SCLC cells were co-transfected with GFP and vector, WT-RB, PSM-RB and p16 ink4a expression plasmids using BES-mediated calcium phosphate as previously described (Knudsen et al., 1998a,b and c) . For transfection of SCLC cells the Tfx-50 reagent was used and a H2B-GFP fusion protein expression plasmid (a gift of Dr G Wahl, Salk Institute) was used in place of GFP. BrdU staining was carried out as previously described (Knudsen et al., 1998b and c) . Cells were subsequently labeled and stained for BrdU incorporation. The percentage of transfected (GFP-positive) cells which incorporated BrdU was determined by counting coverslips. Data shown is from at least two independent experiments with at least 100 transfected cells scored per experiment (ND=not determined). (a) PSM-RB inhibits cell cycle progression of RBpositive tumor cell lines. The date for RD cells and LNCaP cells has been previously published (Knudsen et al., 1998b and c) (b) The eect of PSM-RB on speci®c RB-de®cient tumor cell lines 1 and 2) or U20S (lanes 3 and 4) cells were co-transfected with either vector (lanes 1 and 3) or PSM-RB (lanes 2 and 4) and a plasmid carrying a puromycin selection marker (pBABE-PURO). Co-transfection of pBABE-PURO and PSM-RB or vector control was carried out as previously described (Knudsen et al., 1998a) . For the selection of C33-A and U2OS cells 2.5 mg/ml of puromycin (Sigma) was utilized. After 48 h virtually all untransfected cells were killed at this concentration. After rapid selection with puromycin, selected cells were harvested. Lysates of various transfections were prepared and equal protein was resolved by 7.5% SDS ± PAGE, transferred to Immobilon-P, and RB proteins were detected by immunoblotting with the 851 polyclonal antibody. The cyclin A protein was detected using the Santa Cruz Biotechnology sc-751 antibody. (b) Expression of Cyclin A in PSM-RB expressing C33-A cells. C33-A or U2OS cells were transfected and subjected to selection as described above. Total equal protein was resolved on either 7.5% or 10% SDS ± PAGE, transferred to Immobilon-P. RB and cyclin A proteins were then detected by immunoblotting. (c) Inhibition of proliferation in C33-A cells. C33-A cells were co-transfected with either vector or PSM-RB and a puromycin selectable marker, the cells were subjected to rapid selection and then allowed to form colonies over the course of 8 days. Plates were then stained with crystal violet, and shown are representative from these experiments. (d) Failure to achieve stable expression of PSM-RB. C33-A cells were transfected as described above and colonies were isolated using cloning rings. Isolated colonies were tested for the expression of PSM-RB. Although PSM-RB is present in the rapidly selected cells this protein is not present in any of the stable cell clones positive cells exhibited an aberrant nuclear morphology (Figure 3a) . This suggested that these cells may be undergoing cell death. To test this hypothesis we used terminal deoxynucleotidyl transferase end labeling (TUNEL) assays in situ, wherein only those cells with cleaved DNA are labeled by terminal deoxyunucleotidyl transferase. As a control for cell death in C33-A cells, we treated the cells with 50 mM of cisplatin (CDDP) for 12 h, ®xed, and identi®ed those cells undergoing cell death by TUNEL assay (Figure 3b) . We found that greater than 30% of CDDP-treated C33-A cells stained TUNEL-positive, whereas less than 5% of untreated C33-A cells stained TUNEL-positive (Figure 3b) . At 48 h post-transfection, the 7S-SE and PSM-RB transfected cells exhibited only basal levels of cells staining positive by TUNEL (Figure 3b ). However, after 5 days in culture greater than 35% of the PSM-RB expressing cells scored positive for TUNEL, as compared to the approximately 5% of cells observed with 7S-SE transfected cells. These data illustrate that although C33-A cells are resistant to the cell cycle inhibitory eects of PSM-RB, PSM-RB induces cell death, thereby leading to a strong inhibition of proliferation.
Figure 3 PSM-RB induces cell death in C33-A cells. (a) C33-A cells were transfected with plasmids encoding the constitutively active RB protein, PSM.7-LP, or a non-functional RB protein, 7S-SE. Transfected cells were subjected to immunostaining as follows: to detect RB expression in transfected cells the 851 polyclonal antibody and FITC-conjugated secondary antisera were utilized (left panel); TUNEL staining was utilized to detect fragmented DNA using biotin-conjugated dUTP and rhodamineconjugated streptavidin (middle panel); total nuclei were stained by Hoechst (right panel). For RB immunostaining, cells were ®xed in 3.7% formaldehyde in PBS and permeabilized in 0.3% Triton X-100 in PBS. Permeabilized cells were incubated with the 851 antibody (1 : 100 dilution) in IF buer (PBS, 5 mg/ml BSA, and 0.5% NP-40) for 1 h at 378C. Cells were washed with PBS and then reacted with a 1 : 100 dilution of a FITC conjugated donkey-anti-Rabbit secondary for 1 h at 378C. TUNEL staining was carried out as described in the manufacturer's protocol (with the exception of the ®xation and permeabilization steps) (Upstate Biotechnology). (b) C33-A cells were either treated with the DNA damaging agent cisplatin (CDDP), left untreated, transfected with PSM.7-LP or transfected with 7S-SE. Cells treated with CDDP were ®xed for TUNEL staining 12 h after treatment. Cells transfected with PSM.7-LP or 7S-SE were ®xed for TUNEL staining at the times given post transfection
The results presented demonstrate that constitutively active PSM-RB inhibits cell cycle progression in a broad-range of tumor types, consistent with the hypothesis that RB inactivation is required for cell cycle advancement. Importantly, PSM-RB was capable of arresting cell cycle progression in a number of cell types which are resistant to the eects of either wildtype RB or p16 ink4a (Figure 1 ). However, we identi®ed a tumor cell line which is resistant to the cell cycle inhibitory eects of PSM-RB, demonstrating that tumor cells can bypass the requirement for RB phosphorylation, thus relieving the dependency of cell cycle progression on RB inactivation (Figure 2) . Lastly, we observed that cells which are resistant to the cell cycle inhibitory eects of PSM-RB are still inhibited for cellular proliferation by PSM-RB. We demonstrate that this inhibition of proliferation is caused by PSM-RBmediated induction of programmed cell death, showing for the ®rst time that RB inhibits cellular proliferation through at least two distinct mechanisms (Figure 3) .
It had been previously hypothesized that phosphorylation of RB is required for cell cycle progression (Weinberg, 1995) . In support of this hypothesis, we demonstrated that constitutively active RB inhibits cell cycle progression in cells either containing or lacking an endogenous RB protein. This point is particularly salient in that RB is widely mutated or lost in human tumors, and other known tumor suppressor proteins, such as p16 ink4a only arrest cells which express functional endogenous RB protein (Lukas et al., 1995) . In addition, since the growth inhibitory activity of RB acts downstream of the proto-oncogenes Cyclin D1 and CDK4, we expect that introduction of PSM-RB should also arrest cell cycle progression of tumor cells overexpressing CDK4 or Cyclin D1. As such, PSM-RB acts as a broad-range growth inhibitor, capable of short-circuiting the in¯uence of other upstream mutations on uncontrolled cell cycle progression. Surprisingly, we found that inactivation of RB is not an absolute requirement for cell cycle progression in all cells, as we showed that a speci®c RB-de®cient cell line (C33-A) is resistant to the in¯uence of constitutively active PSM-RB on cell cycle progression. How C33-A cells evade the eects of RB on cell cycle progression is still a focus of study. Protein activities which antagonize RB could lead to such a phenotype, and the nature of such cellular and viral proteins have been previously described (Sidle et al., 1996; Wang et al., 1994) . Importantly, C33-A cells are HPV-negative and thus the short-circuiting of RB-mediated cell cycle arrest is not due to the expression of the HPV E7 protein. Furthermore, a large number of biochemical studies on RB have been carried out in C33-A cells and it is known that the function of RB in protein binding and repressing transcription are intact (Knudsen and Wang, 1997; Whitaker et al., 1998) . However, it is possible that cellular proteins which can inactivate RB may be present in abundance in C33-A cells. Alternatively, key proteins which cooperate with RB to induce cell cycle arrest could be absent in C33-A cells (Trouche et al., 1997) . The absence of such a factor could explain why these cells fail to arrest in response to PSM-RB. Presumably the failure of RB to signal to its down-stream targets is responsible for the failure of PSM-RB to arrest these cells. We have shown that RB inhibits the expression of cyclin A during G1 arrest and causes an overall reduction in CDK2/cyclin activity (Knudsen et al., 1998a) . In C33-A cells, which fail to respond to PSM-RB, we ®nd that cyclin A is not down-regulated, indicating that in these cells the pathway linking RB to cyclin A is compromised. Recently, it has been shown that a leukemic cell line fails to arrest in response to a protein similar to PSM-RB (Hoshikawa et al., 1998) . Whether this mutant is eective in arresting other cell lines or whether RB signals to downstream targets in these cells has yet to be determined.
Extended study in C33-A cells indicated that although PSM-RB does not inhibit cell cycle progression of this cell line, introduction of PSM-RB does strongly inhibit cellular proliferation. Analysis of these cells indicated that PSM-RB inhibits cellular proliferation through the induction of cell death. These results are the ®rst to show that RB can inhibit cellular proliferation through two distinct mechanisms, the inhibition of cell cycle progression and the induction of cell death. We hypothesize that PSM-RB induced cell death is due to a con¯ict between the continued cell cycle progression of these cells and the complexes which PSM-RB assembles. Presumably the induction of cell death re¯ects a security mechanism to eliminate those cells which are no longer dependent on the environmental signals which trigger the dephosphorylation of RB. Overall the ®nding that activated alleles of RB trigger cell death suggest that in instances when RB is dephosphorylated prior to apoptosis, the dephosphorylation of RB itself may be assisting in the death of the cell (Wang, 1998) .
In summary, the data presented highlight the potency of constitutively active RB as a broad-range growth inhibitor, and describes a novel mechanism for the growth-inhibitory action of RB. These data underscore the multiple pathways utilized by RB in the prevention of tumorigenesis and provide the basis for new investigations into RB function.
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